Harnessing the mTOR Pathway for Tuberculosis Treatment
Tuberculosis (TB) remains as one of the leading killer infectious diseases of humans. At present, the standard therapeutic regimen to treat TB comprised of multiple antibiotics administered for a minimum of six months. Although these drugs are useful in controlling TB burden globally, they have not...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2018-01-01
|
| coleção: | Frontiers in Microbiology |
| Assuntos: | |
| Acesso em linha: | http://journal.frontiersin.org/article/10.3389/fmicb.2018.00070/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|